A specific self-administered health-related quality of life questionnaire for sarcopenia, the sarcopenia and Quality of life (SarQol®) has been recently developed.The Pasieka Quality of life questionnaire (PAS-Qol) is a specific self-administered quality of life questionnaire for patients with primary hyperparathyroidism. The questionnaire is an assessment tool to find out how primary hyperparathyroidism affected patients' lifestyle and wellbeing. Sarcopenia and low quality of life are widely found among patients suffering from primary hyperparathyroidism.

The study included both men and women diagnosed with primary hyperparathyroidism and community-dwelling adults with no known hyperparathyroidism disorder. Both groups were assessed with the SarQol questionnaire, and the hyperparathyroidism group was also assessed with the PAS-Qol questionnaire.A comprehensive statistical analysis was conducted on the dataset, encompassing both descriptive and inferential methodologies.

Of the 100 included individuals 80% were women, with a mean age of 63,8years.Mean overall scores of the SarQol for the normal group was 72.6 (SD=14,9) and for the hyperparathyroidism group 63.7 (SD= 15,1). There was a statistically significant difference (p=0.006), suggesting that individuals with hyperparathyroidism generally had lower quality of life scores compared to those without the condition. Between the quality-of-life scores there is a significant negative correlation suggesting that as the SarQol score increases PAS-Qol score tends to decline in primary hyperparathyroidism (negative correlation -0.444**, p=0.001).

The study highlights the potential interconnectedness between these two conditions, sarcopenia and primary hyperparathyroidism, and their impact on patients' overall well-being, and emphasizes the need for comprehensive management strategies to enhance patients' quality of life.